Merck’s Molnupiravir May Be Tied To New Coronavirus Mutations, Study Suggests

Bloomberg (2/1, Lauerman) reports Merck & Co.’s COVID-19 treatment molnupiravir (Lagevrio) “is giving rise to new mutations of the virus in some patients, according to a study.” Mutations tied to use of the drug “have been identified in viral samples take...